Clinical Trials in Quanzhou, China
3 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Severe Asthma
AstraZeneca400 enrolled75 locationsNCT07363642
Recruiting
Not Applicable
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
Cardiovascular Diseases
AstraZeneca3,000 enrolled69 locationsNCT06909773
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled77 locationsNCT07043725
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Not Applicable
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
Type 1 Diabetes
Second Xiangya Hospital of Central South University400 enrolled10 locationsNCT07097818
Recruiting
Phase 3
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Hutchmed316 enrolled53 locationsNCT06387069
Recruiting
Not Applicable
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
Gastric Cancer
Nanfang Hospital, Southern Medical University344 enrolled12 locationsNCT05450835
Recruiting
Phase 2
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.134 enrolled28 locationsNCT06897579
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
Cervical CancerNeuroendocrine NeoplasmWomen+2 more
Fujian Maternity and Child Health Hospital300 enrolled9 locationsNCT06276309
Recruiting
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Tongji Hospital300 enrolled4 locationsNCT05717738
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University240 enrolled10 locationsNCT05593081